Skip to main content
Journal of Patient-Reported Outcomes
Fig. 1 | Journal of Patient-Reported Outcomes

Fig. 1

From: Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

Fig. 1

CONSORT flow diagram

CONSORT flow diagram of the entire study period is presented in the supplementary appendix Figure S1

Kd; Carfilzomib-dexamethasone, p; patient, q; questionnaires (completed items for calculating the EORTC QLQ-C30 summary score)

Back to article page